Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities Growth (5y) (2015 - 2026)
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Cash from Investing Activities Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn |
| 10 | Madrigal Pharmaceuticals | 15.77 Bn | 14.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.59% |
| Mar 31, 2026 | 50.59% |
| Dec 31, 2025 | 50.61% |
| Sep 30, 2025 | -33.15% |
| Jun 30, 2025 | 19.84% |
| Mar 31, 2025 | 26.57% |
| Dec 31, 2024 | -9.47% |
| Sep 30, 2024 | -55.73% |
| Jun 30, 2024 | -39.86% |
| Mar 31, 2024 | 97.55% |
| Dec 31, 2023 | -75.17% |
| Sep 30, 2023 | 17.36% |
| Jun 30, 2023 | 45.95% |
| Mar 31, 2023 | -12.84% |
| Dec 31, 2022 | 61.27% |
| Sep 30, 2022 | 42.41% |
| Jun 30, 2022 | 99.66% |
| Mar 31, 2022 | 48.81% |
| Dec 31, 2021 | 9.19% |
| Sep 30, 2021 | 26.82% |